Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) EBITDA Margin (2016 - 2025)

Northwest Biotherapeutics' EBITDA Margin history spans 16 years, with the latest figure at 229.61% for Q4 2025.

  • Quarterly results put EBITDA Margin at 229.61% for Q4 2025, up 1123567.0% from a year ago — trailing twelve months through Dec 2025 was 4749.27% (up 130608.0% YoY), and the annual figure for FY2025 was 4749.27%, up 130608.0%.
  • EBITDA Margin for Q4 2025 was 229.61% at Northwest Biotherapeutics, up from 13275.0% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 229.61% in Q4 2025 to a low of 14645.8% in Q2 2025.
  • The 5-year median for EBITDA Margin is 4722.25% (2023), against an average of 5785.12%.
  • The sharpest move saw EBITDA Margin skyrocketed 37381755bps in 2021, then crashed -1107012bps in 2025.
  • Year by year, EBITDA Margin stood at 2871.14% in 2021, then fell by -6bps to 3044.89% in 2022, then plummeted by -55bps to 4722.25% in 2023, then tumbled by -133bps to 11006.06% in 2024, then skyrocketed by 102bps to 229.61% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 229.61%, 13275.0%, and 14645.8% for Q4 2025, Q3 2025, and Q2 2025 respectively.